Skip to main content
SYNGENE · Health Care · 2026-08-07

Syngene International Ltd

Stage 4 · wk 3In scan: Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹403.7
+0.99% today
₹16,249 Cr · Mid cap
About this companyHealth Care· Labs & Life Sciences Services
Expand ▾

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Visit company website →
P/E (TTM)
58.6
Forward 36.0
Earnings Growth (YoY)
-19.5%
Revenue +1.8%
ROE
+6.6%
Profit margin +8.5%
Dividend Yield
0.27%
P/B 3.9
vs 52W High
-43.5%
₹385.9 lo₹714 hi
43.5% below 52W high — deep Stage 4 damage
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 3
1w13w26w
Week 3 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-20.0%
200 DMA: ₹504.8 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.78x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
MA20 rolling over · -2.9% vs MA50 -4.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Labs & Life Sciences Services
↑ Building
Stage 2%
33.3%
20d Δ
+16.7pp
1M return
+18.9%
3M return
+20.0%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Labs & Life Sciences Services Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 22w
S4 17w
S2 22w
S4 23w
S4 16w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 22w → S3 9w → S4 6w → S1 7w → S4 17w → S1 2w → S2 22w → S3 7w → S4 23w → S1 10w → S4 11w → S1 3w → S4 16w → S1 9w → S4 3w current
Total tracked: 168 weeks across 15 stage runs.
1M
-2.8%
3M
-11.9%
6M
-13.7%
YTD
-38.4%
1Y
-44.1%
Scan Membership
Breakout Watch
Latest: 2024-07-30
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S4
Wk 3 · Vol x
2026-08-06S4
Wk 3 · Vol x
2026-08-05S4
Wk 3 · Vol x
2026-08-04S4
Wk 3 · Vol x
2026-08-03S4
Wk 3 · Vol x
2026-07-31S4
Wk 2 · Vol x
2026-07-30S4
Wk 2 · Vol x
2026-07-29S4
Wk 2 · Vol x
2026-07-28S4
Wk 2 · Vol x
2026-07-27S4
Wk 2 · Vol x
2026-07-24S4
Wk 1 · Vol x
2026-07-23S4
Wk 1 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹427.3
200 DMA
₹504.8
52W High
₹714
52W Low
₹385.9
5D Low
₹399.8
Resistance levels (recent highs)
20d High
₹420.5
60d High
₹471.4
120d High
₹482.5
250d High
₹704.8
Next resistance
+4.2%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.